Vinpocetine attenuates lipid accumulation and atherosclerosis formation

Biochemical and Biophysical Research Communications

Volumn 434, Issue 3, 2013, Pages 439-443

  Cai, Yujun ^a   Li, Jian Dong ^b   Yan, Chen ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Macrophage; Oxidized LDL; Vinpocetine

Indexed keywords

APOLIPOPROTEIN E; OXIDIZED LOW DENSITY LIPOPROTEIN; VINPOCETINE; LOW DENSITY LIPOPROTEIN; OLR1 PROTEIN, MOUSE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; VINCA ALKALOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; FOAM CELL; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIPID STORAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; FAT INTAKE; FLUORESCENT ANTIBODY TECHNIQUE; LIPID METABOLISM; METABOLISM; MOUSE MUTANT; PATHOLOGY;

MURINAE; MUS;

ANIMALS; ATHEROSCLEROSIS; CELL LINE; DIETARY FATS; FLUORESCENT ANTIBODY TECHNIQUE; LIPID METABOLISM; LIPOPROTEINS, LDL; MACROPHAGES; MICE; MICE, KNOCKOUT; SCAVENGER RECEPTORS, CLASS E; VINCA ALKALOIDS;

MLCS; MLOWN;

EID: 84880487718     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.03.092     Document Type: Article

References (23)

1. R. Ross, The pathogenesis of atherosclerosis: a perspective for the 1990s, Nature 362 (1993) 801-809.
2. R. Ross, Inflammation or atherogenesis, N. Engl. J. Med. 340 (1999) 115-126.
3. P. Libby, Inflammation in atherosclerosis, Nature 420 (2002) 868-874.
4. C.M. Ballantyne, Low-density lipoproteins and risk for coronary artery disease, Am. J. Cardiol. 82 (1998) 3Q-12Q.
5. J.P. Halcox, J.E. Deanfield, Beyond the laboratory: clinical implications for statin pleiotropy, Circulation 109 (2004) II42-II-48.
6. S. Mitra, T. Goyal, J.L. Mehta, Oxidized LDL, LOX-1 and atherosclerosis, Cardiovasc. Drugs Ther. 25 (2011) 419-429.
7. R. Yoshimoto, Y. Fujita, A. Kakino, S. Iwamoto, T. Takaya, T. Sawamura, The discovery of LOX-1, its ligands and clinical significance, Cardiovasc. Drugs Ther. 25 (2011) 379-391.
8. E. Bagoly, G. Fehér, L. Szapáry, The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies, Orv. Hetil. 148 (2007) 1353-1358.
9. R. Balestreri, L. Fontana, F. Astengo, A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction, J. Am. Geriatr. Soc. 35 (1987) 425-430.
10. N. Tamaki, S. Matsumoto, Agents to improve cerebrovascular circulation and cerebral metabolism - vinpocetine, Nippon Rinsho 43 (1985) 376-378.
11. A. Szobor, M. Klein, Ethyl apovincaminate therapy in neurovascular diseases, Arzneimittelforschung 26 (1976) 1984-1989.
12. P. Bonoczk, B. Gulyas, V. Adam-Vizi, A. Nemes, E. Karpati, B. Kiss, M. Kapas, C. Szantay, I. Koncz, T. Zelles, A. Vas, Role of sodium channel inhibition in neuroprotection: effect of vinpocetine, Brain Res. Bull. 53 (2000) 245-254.
13. K.-I. Jeon, X. Xu, T. Aizawa, J.H. Lim, H. Jono, D.-S. Kwon, J.-I. Abe, B.C. Berk, J.-D. Li, C. Yan, Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism, Proc. Natl. Acad. Sci. USA 107 (2010) 9795-9800.
14. Y. Cai, W.E. Knight, S. Guo, J.D. Li, P.A. Knight, C. Yan, Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration, J. Pharmacol. Exp. Ther. 343 (2012) 479-488.
15. P. Nigro, K. Satoh, M.R. O'Dell, N.N. Soe, Z. Cui, A. Mohan, J. Abe, J.D. Alexis, J.D. Sparks, B.C. Berk, Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice, J. Exp. Med. 208 (2010) 53-66.
16. 2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy, Circ. Res. 105 (2009) 956-964.
17. Q. Xu, Mouse models of arteriosclerosis: from arterial injuries to vascular grafts, Am. J. Pathol. 165 (2004) 1-10.
18. R. Yang, L. Powell-Braxton, A.K. Ogaoawara, N. Dybdal, S. Bunting, O. Ohneda, H. Jin, Hypertension and endothelial dysfunction in apolipoprotein E knockout mice, Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2762-2768.
19. J. Chen, P.J. Kuhlencordt, J. Astern, R. Gyurko, P.L. Huang, Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice, Circulation 104 (2001) 2391-2394.
20. D. Kim, S.D. Rybalkin, X. Pi, Y. Wang, C. Zhang, T. Munzel, J.A. Beavo, B.C. Berk, C. Yan, Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance, Circulation 104 (2001) 2338-2343.
21. J.L. Mehta, N. Sanada, C.P. Hu, J. Chen, A. Dandapat, F. Sugawara, H. Satoh, K. Inoue, Y. Kawase, K. Jishage, H. Suzuki, M. Takeya, L. Schnackenberg, R. Beger, P.L. Hermonat, M. Thomas, T. Sawamura, Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet, Circ. Res. 100 (2007) 1634-1642.
22. S.J. White, G.B. Sala-Newby, A.C. Newby, Overexpression of scavenger receptor LOX-1 in endothelial cells promotes atherogenesis in the ApoE(-/-) mouse model, Cardiovasc. Pathol. 20 (2011) 369-373.
23. J. Chen, Y. Liu, H. Liu, P.L. Hermonat, J.L. Mehta, Molecular dissection of angiotensin II-activated human LOX-1 promoter, Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1163-1168.